Norms for nutritional assessment of American adults by upper arm anthropometry

CW Bishop, PE Bowen, SJ Ritchey - The American journal of clinical …, 1981 - Elsevier
Age- and sex-specific percentile distributions for the mid-upper arm circumferences, triceps
skinfold thicknesses, and mid-upper arm muscle circumferences of American adults were …

Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men

…, J Tietyen-Clark, P Oeltgen, CW Bishop - Archives of internal …, 1988 - jamanetwork.com
• The effect of psyllium hydrophilic mucilloid on serum cholesterol levels was investigated in
26 men with mild to moderate hypercholesterolemia (range of cholesterol level, 4.86 to 8.12 …

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4

…, SM Sprague, ME Williams, CW Bishop - American Journal of …, 2004 - Elsevier
Background: Calcitriol lowers parathyroid hormone (PTH) levels in patients with chronic
kidney disease (CKD) stages 3 and 4, but its use is limited by a low therapeutic index and …

Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease

…, S Lee, PM Petkovich, CW Bishop - American journal of …, 2016 - karger.com
Background/Aims: Vitamin D insufficiency and secondary hyperparathyroidism (SHPT) are
associated with increased morbidity and mortality in chronic kidney disease (CKD) and are …

Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease

…, A Ashfaq, M Petkovich, CW Bishop - American journal of …, 2019 - karger.com
Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT)
and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal …

Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism

…, DM Kyllo, LL Douglass, CW Bishop… - American journal of …, 2000 - Elsevier
Hypercalcemia and hyperphosphatemia frequently necessitate vitamin D withdrawal in
hemodialysis patients with secondary hyperparathyroidism. In short-term trials, doxercalciferol (1α…

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a …

…, DM Kyllo, LL Douglass, CW Bishop… - American journal of …, 2001 - Elsevier
Most reports on the effectiveness and side effects of oral versus parenteral calcitriol or
alfacalcidol in hemodialysis patients with secondary hyperparathyroidism show no advantage of …

Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism

…, BS Levine, RB Mazess, DM Kyllo, CW Bishop… - Kidney international, 1997 - Elsevier
Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D 2 in hemodialysis
patients with moderate to severe secondary hyperparathyroidism. Calcitriol, as used for treating …

Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease

…, JA White, JZ Melnick, CW Bishop - American Journal of …, 2015 - karger.com
Background/Aims: Vitamin D insufficiency drives secondary hyperparathyroidism (SHPT)
and is associated with increased cardiovascular mortality in patients with chronic kidney …

[HTML][HTML] Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation

…, J White, S Tabash, S Strugnell, CW Bishop - The Journal of steroid …, 2015 - Elsevier
Vitamin D insufficiency is prevalent in chronic kidney disease (CKD) and associated with
secondary hyperparathyroidism (SHPT) and increased risk of bone and vascular disease. …